Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases

Kim Jackson,Sami L. Bahna

DOI: https://doi.org/10.1080/1744666X.2020.1724089

2020-02-09

Expert Review of Clinical Immunology

Abstract:Introduction : The development of new biologic agents has provided definite therapeutic advances but, like with any new medications, safety remains a concern. Areas covered : Using PubMed, we reviewed the literature on the adverse effects (AE) to five biologics approved for asthma and/or allergic diseases: one anti-IgE (omalizumab), three anti-IL5 (mepolizumab, reslizumab, benralizumab), and one anti-IL4 (dupilumab). Expert opinion : Biologic agents approved for asthma and allergic diseases are generally safe. Most common AE are benign and tolerated, though long-term safety is lacking for most of them. A slightly increased risk of anaphylaxis to omalizumab and reslizumab required the inclusion of a black box warning, informing the patient, the need for post-injection observation period, and the provision of epinephrine autoinjectors for self-administration when needed. Hypersensitivity reactions, mainly urticaria and very rarely serum sickness have occurred.

immunology